Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Find the latest Drugs in Development and Pipeline Prospector News of Frequency Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Frequency Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
19 Presidential Way Woburn, MA 02801
Telephone
Telephone
781-315-4600

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.


Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Partner/Sponsor/Collaborator: Korro Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger November 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.


Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Korro Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger July 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

FX-322 is a combination of proprietary small molecules designed to restore hearing function by activating inner ear progenitor cells in the cochlea to induce hair cell regeneration and improve hearing function.


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

FX-345 is a combination of two small molecules and, similar to Frequency’s lead hearing candidate FX-322, is designed to restore inner ear cells needed for hearing.


Lead Product(s): FX-345

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-345

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

FX-322, is a small-molecule combination product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss.


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 12, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

FX-322 lead hearing restoration product candidate showed improvement by four subjects in a sentence-in-noise test is designed to regenerate auditory hair cells to restore hearing function.


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Clinical data review from four completed FX-322 clinical studies, including 169 subjects with a range of hearing loss severities and SNHL etiologies (sudden, noise-induced, age-related).


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The U.S. Food and Drug Administration (FDA) recently agreed with speech perception as the primary endpoint for FX-322 development, including for the FX-322-208 study and all future FX-322 studies.


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

FX-322 is a thermoreversible poloxamer that is injected intratympanically as a liquid and transitions to a gel used in adults With severe sensorineural hearing loss.


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Frequency also announced new data from a parallel study demonstrating hearing improvement from a single injection of FX-322. The Company plans to advance further development of FX-322 as a single dose regimen.


Lead Product(s): FX-322

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: FX-322

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY